For context, diarrhoea is reported in approximately 916% of patients taking semaglutide 2.4 mg (Wegovy) according to its UK Summary of Product Characteristics (SmPC, emc), and in a broadly similar range for tirzepatide (Mounjaro) per its UK SmPC
Information supplied to pharmacists Initial limited supplies of GLP-1 therapies should be given to patients who cannot switch to other drug classes
All of us need a lot more these site owners just like you on the internet and also much less spammers
Both drug labels advise caution with alcohol
Some interesting data for obesity and emerging for MASH Many thanks to Ahmad Bahareth, MD for sharing Mazdutide: One of the Most Exciting Obesity Therapies to Watch in 2026 By Innovent Biologics Mazdutide (GLP-1/GCG dual receptor agonist) continues to build momentum with impressive clinical and regulatory achievements, positioning itself as a major competitor in the obesity and metabolic disease landscape
You know a whole lot its almost tough to argue with you (not that I personally would want toHaHa)